Ligand Pharmaceuticals Incorporated – Filings and Transcripts

NASDAQ: LGND
Share price (11/4/26): $316.13
Market cap (11/4/26): $6.324 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/26 Q3

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

Prospectuses and Registrations Filter

Registration of securities for employees

Automatic shelf registration

Registration of securities for employees

Registration of securities for employees

Business combination disclosure

Ownership Filter

Pelthos Therapeutics Inc.

News Filter

Reports Third Quarter 2026 Financial Results

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Acquires Royalty and Milestone Interest in Santen’s Ryjunea® From Sydnexis for $23 Million

Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2026

Reports Second Quarter 2026 Financial Results

Proxies Filter

Additional info about upcoming vote

Additional info about upcoming vote

Additional info about upcoming vote

Additional info about upcoming vote

Definitive proxy

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Confidential treatment order

Scanned paper annual report submission